Novel treatments for cold agglutinin disease

Sigbjorn Berentsen, MD, PhD, Haugesund Hospital, Haugesund, Norway, describes the novel treatment approaches for cold agglutinin disease (CAD), including rituximab, bendamustine, and complement-targeted therapeutics. Additional safety and efficacy data from trials show that sutimlimab and the C3-inhibitor pegcetacoplan are promising treatments for CAD. Dr Berentsen also comments on a retrospective study assessing the use of tyrosine kinase inhibitors (TKIs) such as ibrutinib, which represent alternative therapies for CAD. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
Be the first to comment